Cholyl-lysyl-fluoresceinAlternative Names: NRL972
Latest Information Update: 27 Aug 2015
At a glance
- Originator Norgine
- Class Bile acids and salts; Diagnostic agents
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Liver cirrhosis; Non-alcoholic steatohepatitis
Most Recent Events
- 21 Oct 2005 Phase-II clinical trials in Liver disorders in United Kingdom (unspecified route)